Identification of Patients with Head and Neck Cancer Using Serum Protein Profiles

Archives of Otolaryngology - Head and Neck Surgery

Volumn 130, Issue 1, 2004, Pages 98-104

  Wadsworth, J Trad ^a   Somers, Kenneth D ^a,b   Stack Jr , Brendan C ^c   Cazares, Lisa ^b   Malik, Gunjan ^a,b   Adam, Bao Ling ^a,b   Wright Jr , George L ^a,b   Semmes, O John ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Sentara Cancer Resource Centers   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPANSTIMULIN 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; HEAD CANCER; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NECK CANCER; PATIENT MONITORING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; RADIOIMMUNOASSAY; SQUAMOUS CELL CARCINOMA; VALIDATION PROCESS;

BLOOD PROTEINS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MASS SPECTROMETRY; METALLOPROTEINS; NUCLEAR PROTEINS; RIBOSOMAL PROTEINS; RNA-BINDING PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0345743495     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.130.1.98     Document Type: Article

References (35)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 2003;53:27-43.
3. Gleich LL, Salamone FN. Molecular genetics of head and neck cancer. Cancer Control 2002;9:369-378.
4. Patel V, Leethanakul C, Gutkind JS. New approaches to the understanding of the molecular basis of oral cancer. Crit Rev Oral Biol Med. 2001;12:55-63.
5. Srinivas PR, Srivastava S, Hanash S, Wright GL Jr. Proteomics in early detection of cancer. Clin Chem. 2001;47:1901-1911.
6. Adam BL, Vlahou A, Semmes OJ, Wright GL Jr. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics. 2001;1:1264-1270.
7. Kuwata H, Yip TT, Yip CL, Tomita M, Hutchens TW. Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry. Biochem Biophys Res Commun. 1998;245:764-773.
8. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis. 2000;21:1164-1177.
9. Wright GL Jr. SELDI protein chip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn. 2002;2:549-563.
10. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for early detection of cancer. Nat Rev Cancer. 2003;3:267-275.
11. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002;48:1296-1304.
12. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002;62:3609-3614.
13. Cazares LH, Adam BL, Ward MD, et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res. 2002;8:2541-2552.
14. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-577.
15. Petricoin EF III, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 2002;94:1576-1578.
16. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol. 2001;158:1491-1502.
17. Stack BC Jr, Dalsaso TA, Lee C Jr, et al. Overexpression of MPS antigens by squamous cell carcinomas of the head and neck: immunohistochemical and serological correlation with FDG positron emission tomography. Anticancer Res. 1999;19(6C):5503-5510.
18. Bertone P, Kluger Y, Lan N, et al. SPINE: an integrated tracking database and data mining approach for identifying feasible targets in high-throughput structural proteomics. Nucleic Acids Res. 2001;29:2884-2898.
19. Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan. Ann Nucl Med. 2002;16:263-271.
20. Fernandez-Pol JA, Klos DJ, Hamilton PD. A growth factor-inducible gene encodes a novel nuclear protein with zinc finger structure. J Biol Chem. 1993;268:21198-21204.
21. Fernandez-Pol JA, Klos DJ, Hamilton PD. Metallopanstimulin gene product produced in a baculovirus expression system is a nuclear phosphoprotein that binds to DNA. Cell Growth Differ. 1994;5:811-825.
22. Wadsworth JT, Somers KD, Cazares LH, et al. Serum protein profiles to identify head and neck cancer. Clin Cancer Res. In press.
23. Lin JC, Chen KY, Wang WY, Jan JS, Wei YH. PCR detection of circulating tumor cells in nasopharyngeal carcinoma patients with distant metastasis: effect of enzyme and sampling. Head Neck. 2002;24:591-596.
24. Dietz A, Rudat V, Conradt C, Weidauer H, Ho A, Moehler T. Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy. Head Neck. 2000;22:666-673.
25. Walther EK, Dahlmann N, Gorgulla HT. Tumor markers in the diagnosis and follow-up of head and neck cancer: role of CEA, CA 19-9, SCC, TK, and dTTPase. Head Neck. 1993;15:230-235.
26. Gottschlich S, Folz BJ, Goeroegh T, Lippert BM, Maass JD, Werner JA. A new prognostic indicator for head and neck cancer - p53 serum antibodies? Anticancer Res. 1999;19:2703-2705.
27. Tavassoli M, Brunel N, Maher R, Johnson NW, Soussi T. p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity. Int J Cancer. 1998;78:390-391.
28. Warnakulasuriya S, Soussi T, Maher R, Johnson NW, Tavassoli M. Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. J Pathol. 2000;192:52-57.
29. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996;2:1035-1037.
30. Spafford MF, Koch WM, Reed AL, et al. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosa cells by microsatellite analysis. Clin Cancer Res. 2001;7:607-612.
31. El-Naggar AK, Mao L, Staekel G, et al. Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn. 2001;3:164-170.
32. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000;60:892-895.
33. 6-methylguanine-DNA-methyl transferase, and death associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001;61:939-942.
34. von Eggeling F, Davies H, Lomas L, et al. Tissue-specific microdissection coupled with ProteinChip® array technologies: applications in cancer research. Biotechniques. 2000;29:1066-1070.
35. Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis. 2002;19:319-326.